Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Detailed Positive ABRAXANE Phase III Data Released

December 8th, 2003

Detailed Positive ABRAXANE Phase III Data Released

American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.


Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


A Tiny Machine: UCSB electrical and computer engineers design an infinitesimal computing device October 28th, 2016

The molecular mechanism that blocks membrane receptors has been identified: The work in which the Ikerbasque researcher of the Biofisika Institute Xabier Contreras has participated has been published in the journal Cell October 27th, 2016

How nanoscience will improve our health and lives in the coming years: Targeted medicine deliveries and increased energy efficiency are just two of many ways October 26th, 2016

Chad Mirkin receives nanotechnology prize in Russia October 26th, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project